QHSLab, Inc. Welcomes Dr. Juan D. Oms, MD, FAPA, as Medical Advisor for Psychiatry and Behavioral Health
QHSLab, Inc. (OTCQB: USAQ) has announced the addition of Dr. Juan D. Oms as a medical advisor for psychiatry and behavioral health. Dr. Oms, a board-certified psychiatrist with expertise in behavioral health and substance use disorders, will provide strategic guidance in integrating digital healthcare solutions for mental health and substance abuse needs in primary care settings.
Dr. Oms has contributed to QHSLab's research projects, including studies on digital therapeutic interventions for mental health and chronic pain. Early findings show significant reductions in depression and anxiety symptoms, particularly in patients with severe depression. He has also been integral to the success of the Painless series, a digital health initiative for chronic pain management.
The company aims to expand its offerings in mental health and behavioral health solutions, integrating AI-driven healthcare solutions into primary care settings to improve patient outcomes and enhance practice efficiency.
QHSLab, Inc. (OTCQB: USAQ) ha annunciato l'aggiunta del Dr. Juan D. Oms come consulente medico per la psichiatria e la salute comportamentale. Il Dr. Oms, psichiatra certificato con esperienza nella salute comportamentale e nei disturbi da uso di sostanze, fornirà orientamenti strategici per integrare soluzioni sanitarie digitali per le esigenze di salute mentale e abuso di sostanze negli ambienti di assistenza primaria.
Il Dr. Oms ha contribuito ai progetti di ricerca di QHSLab, inclusi studi su interventi terapeutici digitali per la salute mentale e il dolore cronico. I primi risultati mostrano significative riduzioni nei sintomi di depressione e ansia, particolarmente nei pazienti con depressione severa. È stato anche fondamentale per il successo della serie Painless, un'iniziativa di salute digitale per la gestione del dolore cronico.
L'azienda mira ad espandere la sua offerta di soluzioni per la salute mentale e la salute comportamentale, integrando soluzioni sanitarie basate sull'AI negli ambienti di assistenza primaria per migliorare i risultati dei pazienti e aumentare l'efficienza della pratica.
QHSLab, Inc. (OTCQB: USAQ) ha anunciado la incorporación del Dr. Juan D. Oms como asesor médico en psiquiatría y salud conductual. El Dr. Oms, psiquiatra certificado con experiencia en salud conductual y trastornos por uso de sustancias, brindará orientación estratégica para integrar soluciones de atención médica digital para las necesidades de salud mental y abuso de sustancias en entornos de atención primaria.
El Dr. Oms ha contribuido a los proyectos de investigación de QHSLab, incluidos estudios sobre intervenciones terapéuticas digitales para la salud mental y el dolor crónico. Los primeros hallazgos muestran reducciones significativas en los síntomas de depresión y ansiedad, particularmente en pacientes con depresión severa. También ha sido fundamental para el éxito de la serie Painless, una iniciativa de salud digital para el manejo del dolor crónico.
La empresa tiene como objetivo expandir su oferta en soluciones de salud mental y salud conductual, integrando soluciones de atención médica impulsadas por IA en los entornos de atención primaria para mejorar los resultados de los pacientes y aumentar la eficiencia de la práctica.
QHSLab, Inc. (OTCQB: USAQ)는 Dr. Juan D. Oms를 정신의학 및 행동 건강 분야의 의료 고문으로 추가한다고 발표했습니다. Oms 박사는 행동 건강 및 물질 사용 장애에 대한 전문 지식을 가진 보드 인증 정신과 의사로, 1차 진료 환경에서 정신 건강 및 약물 남용 요구를 위한 디지털 의료 솔루션 통합에 대한 전략적 지침을 제공할 것입니다.
Oms 박사는 QHSLab의 연구 프로젝트에 기여했으며, 정신 건강 및 만성 통증을 위한 디지털 치료 개입에 대한 연구를 포함합니다. 초기 결과는 특히 중증 우울증 환자에서 우울증 및 불안 증상이 상당히 감소했음을 보여줍니다. 그는 또한 만성 통증 관리를 위한 디지털 건강 이니셔티브인 Painless 시리즈의 성공에 핵심적인 역할을 해왔습니다.
회사는 정신 건강 및 행동 건강 솔루션의 제공을 확대하고, 1차 진료 환경에 AI 기반의 의료 솔루션을 통합하여 환자 결과를 개선하고 진료 효율성을 높일 계획입니다.
QHSLab, Inc. (OTCQB: USAQ) a annoncé l'ajout du Dr. Juan D. Oms en tant que conseiller médical en psychiatrie et en santé comportementale. Le Dr. Oms, psychiatre certifié avec une expertise en santé comportementale et en troubles liés à l'usage de substances, fournira des conseils stratégiques pour intégrer des solutions de santé numérique pour les besoins en santé mentale et en abus de substances dans les structures de soins primaires.
Le Dr. Oms a contribué aux projets de recherche de QHSLab, y compris des études sur les interventions thérapeutiques numériques pour la santé mentale et la douleur chronique. Les premiers résultats montrent des réductions significatives des symptômes de dépression et d'anxiété, en particulier chez les patients souffrant de dépression sévère. Il a également été essentiel au succès de la série Painless, une initiative de santé numérique pour la gestion de la douleur chronique.
L'entreprise vise à élargir son offre de solutions en santé mentale et en santé comportementale, intégrant des solutions de santé pilotées par l'IA dans les soins primaires afin d'améliorer les résultats pour les patients et d'optimiser l'efficacité des pratiques.
QHSLab, Inc. (OTCQB: USAQ) hat die Hinzufügung von Dr. Juan D. Oms als medizinischen Berater für Psychiatrie und Verhaltensgesundheit bekannt gegeben. Dr. Oms, ein zertifizierter Psychiater mit Fachkenntnissen in Verhaltensgesundheit und Suchtkrankheiten, wird strategische Anleitung zur Integration digitaler Gesundheitslösungen für psychische Gesundheit und Substanzmissbrauch in der primären Gesundheitsversorgung geben.
Dr. Oms hat zu den Forschungsprojekten von QHSLab beigetragen, einschließlich Studien zu digitalen therapeutischen Interventionen für psychische Gesundheit und chronische Schmerzen. Erste Ergebnisse zeigen signifikante Reduktionen der Symptome von Depression und Angst, insbesondere bei Patienten mit schwerer Depression. Er war auch entscheidend für den Erfolg der Painless-Serie, einer digitalen Gesundheitsinitiative zur Schmerzbewältigung.
Das Unternehmen strebt an, sein Angebot im Bereich der psychischen Gesundheit und Verhaltensgesundheit zu erweitern, indem KI-gesteuerte Gesundheitslösungen in die primäre Gesundheitsversorgung integriert werden, um die Patientenergebnisse zu verbessern und die Effizienz der Praxis zu erhöhen.
- Addition of Dr. Juan D. Oms as medical advisor for psychiatry and behavioral health
- Early research findings show significant reductions in depression and anxiety symptoms using QHSLab's platform
- Expansion of offerings in mental health and behavioral health solutions
- Integration of AI-driven healthcare solutions into primary care settings
- None.
WEST PALM BEACH, FL, Oct. 22, 2024 (GLOBE NEWSWIRE) -- QHSLab, Inc. (the "Company") (OTCQB: USAQ), a leader in digital health and point-of-care technologies designed to empower clinicians with proactive, value-based healthcare solutions, is pleased to announce the addition of Dr. Juan D. Oms, a board-certified psychiatrist with extensive expertise in behavioral health and substance use disorders, as a medical advisor. Dr. Oms will provide strategic guidance in integrating advanced digital healthcare solutions to support the mental health and substance misuse and/or abuse needs of patients in primary care settings.
Dr. Oms completed his medical degree at the Autonomous University of Guadalajara in Jalisco, Mexico, followed by residency training in Psychiatry at Jackson Memorial Hospital in Miami, in association with the University of Miami and the VA Medical Center. He is a Diplomate of the American Board of Psychiatry and Neurology and completed a fellowship in Forensic Psychiatry and a Fellow of the American Psychiatric Association. Over the course of his career, Dr. Oms has developed specialized interests in substance use disorders, serving as Medical Director at several facilities, including Miami Outpatient Detox, where he led the integration of comprehensive outpatient substance use treatment services.
Dr. Oms has also made significant contributions to academic psychiatry, serving as Chairman and Program Director of the Psychiatry Residency Southern Winds Hospital. In addition, he has held various academic appointments as Assistant Clinical Professor at FIU College of Medicine, Saint George University, Ross University School of Medicine, and American University of the Antilles. His commitment to education and innovative patient care continues as he serves in various leadership roles, including Director of Psychiatry at Ketamine Health Centers, where he pioneered treatments for resistant depression and contributed to clinical research.
Since joining Jackson Behavioral Health in 2020, Dr. Oms has played a key role in developing a co-occurring substance use and mental health inpatient unit and streamlining tele-psychiatric consult services across the Jackson Memorial Hospital System. His expertise in blending traditional and innovative treatment methods aligns with QHSLab’s mission to empower physicians through digital health solutions that improve patient outcomes and enhance practice efficiency.
"We are excited to have Dr. Oms join QHSLab as we expand our offerings in mental health and behavioral health solutions," said Troy Grogan, President and CEO of QHSLab. "His extensive experience and leadership in psychiatry and substance use disorders will greatly benefit our mission to integrate advanced, AI-driven healthcare solutions into primary care settings."
Since joining QHSLab, Dr. Oms has actively contributed to projects evaluating digital therapeutic interventions for mental health and chronic pain. These include longitudinal studies assessing the impact of QHSLab’s platform on reducing depression (PHQ-9) and anxiety (GAD-7) scores in primary care patients. Early findings from these studies show significant reductions in depression and anxiety symptoms, particularly in patients with severe depression, highlighting the potential for digital health tools to provide accessible, non-pharmacological treatment options.
Dr. Oms has also been integral to the success of the Painless series—a digital health initiative designed to help patients manage chronic pain through cognitive-behavioral strategies and health journeys. These efforts align with QHSLab’s broader goal to integrate mental health solutions into primary care practices, offering both lifestyle modifications and mental health support for patients with comorbid conditions. The research mentioned above is part of two scientific abstracts submitted to the American Psychiatric Association Annual Meeting.
"Dr. Oms's expertise, background in academia, and dedication to both mental health and digital innovation bring a wealth of knowledge to QHSLab,” said Marcos A. Sanchez-Gonzalez, MD, PhD,. VP of Medical & Scientific Affairs at QHSLab. “We are thrilled to have him on board as he actively contributes to advancing our digital health initiatives. His work will play a pivotal role in expanding our capabilities in behavioral health and chronic care management, ultimately improving patient outcomes in primary care settings and beyond."
QHSLab, Inc. continues to push the boundaries of digital healthcare, and Dr. Oms’s insights will help accelerate the company’s growth in behavioral health services, allowing primary care physicians to better assess, monitor, and manage mental health conditions in the patients they serve.
For more information about QHSLab and its digital health solutions, please visit qhslab.com/research.
About QHSLab, Inc.
QHSLab, Inc. (OTCQB: USAQ) is a medical device company providing digital healthcare solutions and point-of-care-diagnostic tests to primary care physicians. Digital healthcare allows doctors to assess patient responses quickly and effectively using advanced artificial intelligence algorithms. Digital healthcare can also remotely monitor patients’ vital signs and evaluate the effects of prescribed medicines and treatments on patients’ health through real-time data transferred from patient to doctor. QHSLab, Inc. also markets and sells point-of-care, rapid-response diagnostic tests used in the primary care practice. QHSLab, Inc.’s products and services are designed to help physicians improve patient monitoring and medical care while also improving their revenues.
Forward-Looking Statements
Certain matters discussed in this press release are ‘forward-looking statements’ intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace, future revenues, future products, and potential future results and acquisitions are examples of such forward-looking statements. Forward-looking statements are generally identified by words such as ‘may,’ ‘could,’ ‘believes,’ ‘estimates,’ ‘targets,’ ‘expects,’ or ‘intends,’ and other similar words that express risks and uncertainties. These statements are subject to numerous risks and uncertainties, including, but not limited to, the timing of the introduction of new products, the inherent discrepancy in actual results from estimates, projections, and forecasts made by management, regulatory delays, changes in government funding and budgets, and other factors, including general economic conditions, not within the Company’s control. The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release. The Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Investor Relations Contact:
Olivia Giamanco
QHSLab, Inc.
(929) 379-6503
ir@usaqcorp.com
https://twitter.com/QHSLabInc
FAQ
What is QHSLab's stock symbol?
Who is Dr. Juan D. Oms and what is his role at QHSLab?
What research projects has Dr. Oms contributed to at QHSLab?
What is the Painless series mentioned in the press release?
